此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项在复发或难治性多发性骨髓瘤参与者中比较 Talquetamab 联合达雷妥尤单抗或联合达雷妥尤单抗和泊马度胺与达雷妥尤单抗联合泊马度胺和地塞米松的研究 (MonumenTAL-3)

2026年11月2日 更新者:Janssen Research & Development, LLC

一项比较 Talquetamab 联合 Daratumumab (SC) 和 Pomalidomide (Tal-DP) 或 Talquetamab (SC) 联合 Daratumumab SC (Tal-D) 与 Daratumumab SC、泊马度胺和地塞米松 (DPd) 的 3 期随机研究,参与者为至少接受过 1 种既往治疗的复发或难治性多发性骨髓瘤

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).

研究概览

研究类型

介入性

注册 (实际的)

864

阶段

  • 第三阶段

扩展访问

得到正式认可的 出售给公众。 查看扩展访问记录。

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100034
        • Peking University First Hospital
      • Beijing、中国、100006
        • Peking Union Medical College Hospital
      • Changchun、中国、130021
        • The First Hospital of Jilin University
      • Changsha、中国、410000
        • The second Xiangya Hospital of Central South University
      • Chaoyang District、中国、100020
        • Beijing Chaoyang Hospital
      • Chengdu、中国、610072
        • Sichuan Academy of Medical Science Sichuan Provincial Peoples Hospital
      • Fuzhou、中国、350001
        • Fujian Medical University Union Hospital
      • Guangzhou、中国、510080
        • Guangdong Provincial People's Hospital
      • Guangzhou、中国、510710
        • Sun Yat Sen University Cancer Center
      • Hangzhou、中国、310003
        • The First Affiliated Hospital Zhejiang University College of Medicine
      • Nanjing、中国、210008
        • Nanjing Drum Tower Hospital
      • Shanghai、中国、200065
        • Tongji Hospital of Tongji University
      • Shanghai、中国、200434
        • Shanghai Fourth People s Hospital
      • Shenzhen、中国、518036
        • Peking University Shenzhen Hospital
      • Suzhou、中国、215006
        • First Affiliated Hospital SooChow University
      • Tianjin、中国、300320
        • Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science
      • Tianjin、中国、300060
        • Tianjin cancer hospital
      • Wuhan、中国、430030
        • Tongji Hospital, Tongji Medical College of HUST
      • Zhengzhou、中国、450008
        • Henan Cancer Hospital
      • Afula、以色列、1834111
        • Ha'Emek Medical Center
      • Be’er Ya‘aqov、以色列、70300
        • Shamir Medical Center Assaf Harofeh
      • Hadera、以色列、3810101
        • Hillel Yaffe Medical Center
      • Haifa、以色列、31096
        • Rambam Medical Center
      • Haifa、以色列、31048
        • Bnai Zion Medical Center
      • Haifa、以色列、34362
        • Carmel Medical Center
      • Jerusalem、以色列、9103102
        • Shaare Zedek Medical Center
      • Nahariya、以色列、22100
        • Galilee Medical Center
      • Petah Tikva、以色列、49100
        • Beilinson medical center
      • Ramat Gan、以色列、52621
        • Sheba Medical Center
      • Safed、以色列、13100
        • Ziv Medical Center
      • Tel Aviv、以色列、6423906
        • Sourasky (Ichilov) Medical Center
      • Kaohsiung City、台湾、83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Kaohsiung City、台湾、80756
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Taichung、台湾、40447
        • China Medical University Hospital
      • Tainan、台湾、704
        • National Cheng Kung University Hospital
      • Taipei、台湾、10048
        • National Taiwan University Hospital
      • Ankara、土耳其(türkiye)、06680
        • Liv Hospital Ankara
      • Ankara、土耳其(türkiye)、06200
        • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Hematology Unit
      • Ankara、土耳其(türkiye)、06590
        • Ankara University Medical Faculty
      • Antalya、土耳其(türkiye)、07100
        • Antalya Egitim ve Arastirma Hastanesi
      • Istanbul、土耳其(türkiye)、34093
        • Istanbul University Istanbul Medical Faculty
      • Istanbul、土耳其(türkiye)、34214
        • Medipol Mega University Hospital
      • Istanbul、土耳其(türkiye)、34153
        • Cerrahpasa Tip Fakultesi Prof. Dr. Murat Dilmener Hastanesi
      • Izmir、土耳其(türkiye)、35330
        • Dokuz Eylul University Medical Faculty
      • Samsun、土耳其(türkiye)、55139
        • Ondokuz Mayis University
      • Barretos、巴西、14784 400
        • Fundacao Pio XII
      • Belo Horizonte、巴西、30150-221
        • Santa Casa de Misericordia de Belo Horizonte
      • Brasília、巴西、70390-140
        • IDOR - Regional Brasilia
      • Caxias do Sul、巴西、95070 560
        • Fundacao Universidade de Caxias do Sul
      • Curitiba、巴西、81520-060
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Florianópolis、巴西、88020 210
        • Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
      • Natal、巴西、59062-000
        • Liga Norte Riograndense Contra O Cancer
      • Porto Alegre、巴西、90050-170
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Ribeirão Preto、巴西、14051140
        • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
      • Rio de Janeiro、巴西、22775 001
        • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
      • Salvador、巴西、41253-190
        • IDOR - Regional Bahia
      • São Paulo、巴西、01321-001
        • Real e Benemerita Associacao Portuguesa de Beneficencia
      • São Paulo、巴西、01308 901
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • São Paulo、巴西、01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo、巴西、01323-000
        • Hospital Paulistano
      • São Paulo、巴西、04537 081
        • Clinica Medica Sao Germano LTDA
      • São Paulo、巴西、01401 002
        • IDOR - Regional Sao Paulo
      • Athens Attica、希腊、115 28
        • Alexandra General Hospital of Athens
      • Thessaloniki、希腊、546 39
        • Anticancer Hospital of Thessaloniki Theageneio
      • Thessalonikis、希腊、570 10
        • G Papanikolaou Hospital of Thessaloniki
      • Berlin、德国、12203
        • Charite Campus Benjamin Franklin
      • Cologne、德国、50937
        • Universitaetsklinikum Koeln
      • Hamburg、德国、22763
        • Asklepios Klinik Altona
      • Heidelberg、德国、69120
        • Universitaetsklinikum Heidelberg
      • Leipzig、德国、04103
        • Universitaetsklinikum Leipzig
      • Mainz、德国、55131
        • Universitätsmedizin der Johannes Gutenberg Universität
      • Würzburg、德国、97080
        • Universitaetsklinikum Wuerzburg
      • Ancona、意大利、60126
        • A.O. Universitaria Ospedali Riuniti di Ancona
      • Bari、意大利、70124
        • Policlinico di Bari
      • Bologna、意大利、40138
        • Azienda Ospedaliera Policlinico S. Orsola-Malpighi
      • Brescia、意大利、25123
        • Azienda Ospedaliera Spedali Civili di Brescia
      • Catania、意大利、95123
        • PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania
      • Milan、意大利、20162
        • ASST Grande Ospedale Metropolitano Niguarda
      • Milan、意大利、20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Padova、意大利、35128
        • Azienda Ospedaliera Universitaria di Padova
      • Palermo、意大利、90146
        • Ospedale Villa Sofia-Cervello
      • Pavia、意大利、27100
        • Fondazione IRCCS Policlinico San Matteo
      • Reggio Emilia、意大利、42123
        • Arcispedale Santa Maria Nuova - IRCCS
      • Roma、意大利、00193
        • Presidio Ospedaliero Santo Spirito in Sassia
      • San Giovanni Rotondo、意大利、71013
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • Torino、意大利、10126
        • A.O.U. Città della Salute e della Scienza
      • Brno、捷克语、625 00
        • Fakultni nemocnice Brno
      • Hradec Králové、捷克语、500 05
        • Fakultni nemocnice Hradec Kralove
      • Olomouc、捷克语、779 00
        • Fakultni nemocnice Olomouc
      • Ostrava - Poruba、捷克语、708 52
        • Fakultni Nemocnice Ostrava
      • Prague、捷克语、100 34
        • Fakultni nemocnice Kralovske Vinohrady
      • Prague、捷克语、128 08
        • Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
      • Bunkyō City、日本、113 8519
        • Institute of Science Tokyo Hospital
      • Chiba、日本、260-8717
        • Chiba Cancer Center
      • Fukuoka、日本、814-0180
        • Fukuoka University Hospital
      • Gifu、日本、503-8502
        • Ogaki Municipal Hospital
      • Gunma、日本、371-0034
        • Gunma University Hospital
      • Hirakata、日本、573 1191
        • Kansai Medical University Hospital
      • Hyōgo、日本、670-8540
        • Japanese Red Cross Society Himeji Hospital
      • Kamakura-shi、日本、247-8533
        • Shonan Kamakura General Hospital
      • Kashiwa、日本、277 8577
        • National Cancer Center Hospital East
      • Koshigaya、日本、343-8555
        • Dokkyo Medical University Saitama Medical Center
      • Kumamoto、日本、860-8556
        • Kumamoto University Hospital
      • Kyoto、日本、603-8151
        • Kyoto Kuramaguchi Medical Center
      • Matsumoto、日本、399-8701
        • National Hospital Organization Matsumoto Medical Center
      • Niigata、日本、951-8566
        • Niigata Cancer Center Hospital
      • Nishinomiya Shi、日本、663 8501
        • Hyogo Medical University Hospital
      • Sapporo、日本、060-8648
        • Hokkaido University Hospital
      • Sendai、日本、980 8574
        • Tohoku University Hospital
      • Shiwa-gun、日本、028-3695
        • Iwate Medical University Hospital
      • Suita、日本、565 0871
        • The University of Osaka Hospital
      • Tokyo、日本、135 8550
        • The Cancer Institute Hospital of JFCR
      • Ōtake、日本、739-0696
        • National Hospital Organization Hiroshima-Nishi Medical Center
      • Brussels、比利时、1090
        • UZ Brussel
      • Edegem、比利时、2650
        • UZA
      • Hasselt、比利时、3500
        • Virga Jessa Ziekenhuis
      • Liège、比利时、4000
        • CHC MontLegia
      • Ottignies、比利时、1340
        • Clinique Saint Pierre
      • Yvoir、比利时、5530
        • UCL Mont Godinne
      • Créteil、法国、94010
        • APHP - Hopital Henri Mondor
      • Dijon、法国、21000
        • CHU Dijon
      • Lyon、法国、69008
        • Centre Leon Berard
      • Montpellier、法国、34295
        • CHU de Montpellier - Hopital Saint-Eloi
      • Nantes、法国、44093
        • CHU de Nantes hotel Dieu
      • Nice、法国、06202
        • CHU HOPITAL DE L'ARCHET - Hematology
      • Paris、法国、75571
        • CHU Hopital Saint Antoine
      • Pessac、法国、33604
        • CHRU - Hôpital du Haut Lévêque - Centre François Magendie
      • Toulouse、法国、31059
        • Institut Universitaire du cancer de Toulouse-Oncopole
      • Brzozów、波兰、36-200
        • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
      • Gdansk、波兰、80 214
        • Uniwersyteckie Centrum Kliniczne
      • Katowice、波兰、40 519
        • Pratia Onkologia Katowice
      • Kielce、波兰、25 734
        • Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
      • Krakow、波兰、30 688
        • Szpital Uniwersytecki w Krakowie
      • Lublin、波兰、20090
        • Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
      • Olsztyn、波兰、10-228
        • Szpital Kliniczny MSWiA z Warminsko Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii
      • Szczecin、波兰、71-252
        • Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
      • Torun、波兰、87 100
        • Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
      • Warsaw、波兰、02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Wroclaw、波兰、50 367
        • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
    • Arizona
      • Tucson、Arizona、美国、85719
        • The University of Arizona Cancer Center
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • University of Arkansas for Medical Sciences
    • Connecticut
      • Norwalk、Connecticut、美国、06850
        • Norwalk Hospital-oncology
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20007
        • MedStar Georgetown University Hospital
      • Washington D.C.、District of Columbia、美国、20037
        • George Washington University
    • Florida
      • Hollywood、Florida、美国、33021
        • Memorial Healthcare System
      • Miami、Florida、美国、33136
        • University of Miami Health System
    • Illinois
      • Chicago、Illinois、美国、60612
        • University Of Illinois
    • Kansas
      • Westwood、Kansas、美国、66205
        • University of Kansas
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • Tulane University Hospital & Clinics
      • New Orleans、Louisiana、美国、70121-2429
        • Ochsner Health System
    • Maryland
      • Baltimore、Maryland、美国、21205
        • Johns Hopkins University
    • Massachusetts
      • Boston、Massachusetts、美国、02118
        • Boston University Medical Center
      • Boston、Massachusetts、美国、02114
        • Massachusetts General
      • Worcester、Massachusetts、美国、01655
        • University of Massachusetts Medical School
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan Health System
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • University Of Minnesota
    • Mississippi
      • Jackson、Mississippi、美国、39216
        • University of Mississippi Medical Center
    • Missouri
      • St Louis、Missouri、美国、63110-1032
        • Washington University School Of Medicine
    • New Jersey
      • New Brunswick、New Jersey、美国、08901
        • Rutgers Cancer Institute of New Jersey
    • New York
      • New York、New York、美国、10016
        • NYU Langone Health
      • Syracuse、New York、美国、13210
        • SUNY Upstate Medical University
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • University of North Carolina
      • Charlotte、North Carolina、美国、28204
        • Levine Cancer Institute, Carolinas HealthCare System
      • Charlotte、North Carolina、美国、28204
        • Novant Health 1
      • Winston-Salem、North Carolina、美国、27157
        • Wake Forest Baptist Medical Center
      • Winston-Salem、North Carolina、美国、27103
        • Novant Health
    • Ohio
      • Cleveland、Ohio、美国、44106
        • University Hospitals Cleveland Medical Center
      • Columbus、Ohio、美国、43214
        • OhioHealth
      • Columbus、Ohio、美国、43210
        • The Ohio State University Wexner Medical Center - James Cancer Hospital
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107-4215
        • Thomas Jefferson University
    • South Carolina
      • Charleston、South Carolina、美国、29425-8900
        • Medical University of South Carolina
    • Tennessee
      • Memphis、Tennessee、美国、38120
        • Baptist Cancer Center
    • Texas
      • Houston、Texas、美国、77030
        • MD Anderson Cancer Center
      • Houston、Texas、美国、77030
        • Houston Methodist Hospital
      • Lubbock、Texas、美国、79410
        • Joe Arrington Cancer Research Treatment Center
    • Utah
      • Salt Lake City、Utah、美国、84112
        • Huntsman Cancer Institute
    • Virginia
      • Charlottesville、Virginia、美国、22903
        • University of Virginia
      • Richmond、Virginia、美国、23298
        • Virginia Commonwealth University - Massey Cancer Center
    • Washington
      • Seattle、Washington、美国、98109
        • Fred Hutchinson Cancer Research Center
      • Blackpool、英国、FY3 8NR
        • Blackpool Victoria Hospital
      • Dundee、英国、DD1 9SY
        • Ninewells Hospital & Medical School
      • London、英国、W12 0HS
        • Hammersmith Hospital
      • Newcastle upon Tyne、英国、NE7 7DN
        • Newcastle Freeman Hospital
      • Nottingham、英国、NG5 1PB
        • Nottingham City Hospital
      • Plymouth、英国、PL6 8DH
        • University Hospitals Plymouth NHS Trust
      • Sutton、英国、SM2 5PT
        • Royal Marsden Hospital
      • Wolverhampton、英国、WV10 0QP
        • New Cross Hospital
      • Dordrecht、荷兰、3318 AT
        • Albert Schweitzer ziekenhuis-lokatie Dordwijk
      • Eindhoven、荷兰、5631 BM
        • Maxima Medisch Centrum
      • Rotterdam、荷兰、3015
        • Erasmus MC
      • Badalona、西班牙、08916
        • Hosp. Univ. Germans Trias I Pujol
      • Barcelona、西班牙、08041
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona、西班牙、08036
        • Hosp Clinic de Barcelona
      • Barcelona、西班牙、08035
        • Hosp Univ Vall D Hebron
      • El Palmar、西班牙、30120
        • Hosp. Univ. Virgen de La Arrixaca
      • Jerez de la Frontera、西班牙、11407
        • Hosp. de Jerez de La Frontera
      • León、西班牙、24071
        • Hosp. de Leon
      • Madrid、西班牙、28041
        • Hosp. Univ. 12 de Octubre
      • Madrid、西班牙、28034
        • Hosp. Univ. Ramon Y Cajal
      • Madrid、西班牙、28006
        • Hosp. Univ. de La Princesa
      • Madrid、西班牙、28050
        • Hosp Univ Hm Sanchinarro
      • Málaga、西班牙、29010
        • Hosp Virgen de La Victoria
      • Pamplona、西班牙、31008
        • Clinica Univ. de Navarra
      • Salamanca、西班牙、37007
        • Hosp Clinico Univ de Salamanca
      • San Cristóbal de La Laguna、西班牙、38320
        • Hosp. Univ. de Canarias
      • Valencia、西班牙、46017
        • Hosp. Univ. Dr. Peset
      • Busan、韩国、602 812
        • Dong-A University Hospital
      • Gyeonggi-do、韩国、10408
        • National Cancer Center
      • Incheon、韩国、21565
        • Gachon University Gil Medical Center
      • Jeollanam-do、韩国、58128
        • Chonnam National University Hwasun Hospital
      • Jeonju、韩国、54907
        • Jeonbuk National University Hospital
      • Seoul、韩国、03080
        • Seoul National University Hospital
      • Seoul、韩国、05505
        • Asan Medical Center
      • Seoul、韩国、03722
        • Severance Hospital Yonsei University Health System
      • Seoul、韩国、06351
        • Samsung Medical Center
      • Seoul、韩国、06591
        • The Catholic University of Korea Seoul St Marys Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurable disease at screening as defined by any of the following: i) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) (central laboratory); ii) Urine M-protein level >= 200 milligram (mg) per 24 hours (central laboratory); iii) Light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain >= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Relapsed or refractory disease as defined by: i) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria greater than (>) 60 days after cessation of treatment; ii) Refractory disease is defined as less than (<) 25 percent (%) reduction in monoclonal paraprotein (M-protein) or confirmed progressive disease by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
  • Received at least 1 prior line of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide. Participants who have received only 1 prior line of antimyeloma therapy must be considered lenalidomide-refractory (that is, have demonstrated progressive disease by IMWG criteria on or within 60 days of completion of lenalidomide-containing regimen). Participants who have received >=2 prior lines of antimyeloma therapy must be considered lenalidomide exposed
  • Documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria on or after their last regimen
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment

Exclusion Criteria:

  • Contraindications or life-threatening allergies, hypersensitivity, or intolerance to study drug excipients
  • Disease is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody as defined per IMWG consensus guidelines (progression during treatment or within 60 days of completing therapy with an anti-CD38 monoclonal antibody)
  • Received prior pomalidomide therapy
  • A maximum cumulative dose of corticosteroids to >=140 milligrams (mg) of prednisone or equivalent within 14-day period before the first dose of study drug
  • Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
  • Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome), or primary amyloid light chain amyloidosis

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP)

Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug Access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled.

Talquetamab will be administered subcutaneously.

其他名称:
  • JNJ-64407564

Pomalidomide will be administered orally.

Dexamethasone will be administered orally or intravenously.

Daratumumab will be administered subcutaneously.

实验性的:Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd)

Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug-access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled.

Pomalidomide will be administered orally.

Dexamethasone will be administered orally or intravenously.

Daratumumab will be administered subcutaneously.

实验性的:Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D)

Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug-access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled.

Talquetamab will be administered subcutaneously.

其他名称:
  • JNJ-64407564

Dexamethasone will be administered orally or intravenously.

Daratumumab will be administered subcutaneously.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:Up to 6 years 6 months

PFS is defined as time from the date of randomization to the first documentation of disease progression, or death due to any cause, whichever is reported first.

Up to 6 years 6 months

次要结果测量

结果测量
措施说明
大体时间
Overall Response (Partial Response [PR] or Better)
大体时间:Up to 6 years 6 months

Overall response (PR or better) is defined as percentage of participants who have a PR or better per International Myeloma Working Group (IMWG) criteria.

Up to 6 years 6 months
Very Good Partial Response (VGPR) or Better Rate
大体时间:Up to 6 years 6 months

VGPR or better rate is defined as the percentage of participants who achieve a VGPR or better according to IMWG response criteria.

Up to 6 years 6 months
Complete Response (CR) or Better Rate
大体时间:Up to 6 years 6 months

CR or better rate is defined as the percentage of participants who achieve CR or better according to IMWG response criteria.

Up to 6 years 6 months
Overall Minimal Residual Disease (MRD) Negative CR
大体时间:Up to 6 years 6 months

MRD-negative CR is defined as proportion of participants with CR or stringent CR who achieve MRD negativity at a threshold of 10^-5 at any timepoint after the first dose of study drug and before disease progression or start of subsequent antimyeloma therapy.

Up to 6 years 6 months
Overall Survival (OS)
大体时间:Up to 6 years 6 months

OS is defined as the time from the date of randomization to the date of the participant's death.

Up to 6 years 6 months
Progression-free Survival on Next-line Therapy (PFS2)
大体时间:Up to 6 years 6 months

PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.

Up to 6 years 6 months
Time to Next Therapy (TTNT)
大体时间:Up to 6 years 6 months

TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment.

Up to 6 years 6 months
Number of Participants with Adverse Events (AEs)
大体时间:Up to 6 years 6 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 6 years 6 months
Number of Participants with AEs by Severity
大体时间:Up to 6 years 6 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).

Up to 6 years 6 months
Serum Concentrations of Talquetamab
大体时间:Up to 6 years 6 months

Serum concentrations of talquetamab will be reported.

Up to 6 years 6 months
Serum Concentrations of Daratumumab
大体时间:Up to 6 years 6 months

Serum concentrations of daratumumab will be reported.

Up to 6 years 6 months
Number of Participants with Presence of Anti-Drug Antibodies (ADAs) to Talquetamab
大体时间:Up to 6 years 6 months

Number of participants with presence ADAs to talquetamab will be reported.

Up to 6 years 6 months
Number of Participants With Presence of Anti-Drug Antibodies (ADAs) to Daratumumab
大体时间:Up to 6 years 6 months

Number of participants with presence of ADAs to daratumumab will be reported.

Up to 6 years 6 months
Time to Worsening in Symptoms, Functioning, and Overall Health-Related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
大体时间:Up to 6 years 6 months

The MySIm-Q is a disease-specific PRO assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30).

Up to 6 years 6 months
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
大体时间:Up to 6 years 6 months

The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed--length short form derived from the PROMIS Physical Function item bank.

Up to 6 years 6 months
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
大体时间:Up to 6 years 6 months

Time to worsening in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported.

Up to 6 years 6 months
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
大体时间:Up to 6 years 6 months

The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability.

Up to 6 years 6 months
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
大体时间:Up to 6 years 6 months

The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses.

Up to 6 years 6 months
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
大体时间:Up to 6 years 6 months

The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population.

Up to 6 years 6 months
Change From Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
大体时间:Baseline up to 6 years 6 months

The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30.

Baseline up to 6 years 6 months
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
大体时间:Baseline up to 6 years 6 months

The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed-length short form derived from the PROMIS Physical Function item bank.

Baseline up to 6 years 6 months
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
大体时间:Baseline up to 6 years 6 months

Change from baseline in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported.

Baseline up to 6 years 6 months
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
大体时间:Baseline up to 6 years 6 months

The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability.

Baseline up to 6 years 6 months
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
大体时间:Baseline up to 6 years 6 months

The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses.

Baseline up to 6 years 6 months
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
大体时间:Baseline up to 6 years 6 months

The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population.

Baseline up to 6 years 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年10月13日

初级完成 (估计的)

2027年7月30日

研究完成 (估计的)

2028年5月25日

研究注册日期

首次提交

2022年6月22日

首先提交符合 QC 标准的

2022年7月12日

首次发布 (实际的)

2022年7月13日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CR109082
  • 2021-000202-22 (EudraCT编号)
  • 64407564MMY3002 (其他标识符:Janssen Research & Development, LLC)
  • 2023-503467-41-00 (注册表标识符:EUCT number)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅